quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:34:00·141d
PRRelease
Virax Biolabs Group Limited logo

Virax Biolabs' CEO James Foster Outlines Clinical Progress and 2026 Priorities in Latest Annual Letter to Shareholders

VRAX· Virax Biolabs Group Limited
Health Care
Original source

Companies

  • VRAX
    Virax Biolabs Group Limited
    Health Care

Recent analyst ratings

  • Mar 31UpdateH.C. Wainwright$3.00

Related

  • SEC9d
    SEC Form 6-K filed by Virax Biolabs Group Limited
  • PR9d
    Virax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to Shareholders
  • SEC13d
    SEC Form 6-K filed by Virax Biolabs Group Limited
  • INSIDER23d
    SEC Form 3 filed by new insider Haight Nelson M
  • PR23d
    Virax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical Validation
  • INSIDER34d
    SEC Form 3 filed by new insider Mccracken Nigel William
  • SEC36d
    SEC Form 6-K filed by Virax Biolabs Group Limited
  • INSIDER36d
    SEC Form 3 filed by new insider Foster James Alexander Cunliffe
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022